Fresenius Files Tocilizumab Biosimilar With EMA

Follows Earlier Announcement Of Kabi’s US FDA Filing For Actemra/RoActemra Rival

 
• By Dave Wallace

Fresenius Kabi has followed a US filing for its MSB11456 proposed tocilizumab biosimilar with a parallel marketing authorization application in the EU for its rival to RoActemra.

EU US Cogs Flags
Fresenius has now submitted tocilizumab in both the US and EU • Source: Shutterstock

More from Biosimilars

More from Products